BCAB
USDBioAtla Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$0.650
Máximo
$0.678
Mínimo
$0.613
Volume
0.11M
Fundamentos da empresa
Capitalização de mercado
39.5M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
1.01M
Bolsa de valores
NCM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its
Ações relacionadas
DC
Dakota Gold Corp.
INBKZ
First Internet Bancorp 6.0% Fixed-to-Floating Rate Subordinated Notes Due 2029
SBFMW
Sunshine Biopharma Inc. Warrant
ABR
Arbor Realty Trust
SNCRL
Synchronoss Technologies Inc. 8.375% Senior Notes due 2026
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.